Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0432222 (SEM)
 47,337 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Thyroxine-binding globulin (TBG), triiodothyronine (T3), thyroxine (T4) and thyrotropin (TSH) have been determined by radioimmunoassay in plasma of newborn infants and throughout childhood until puberty. Mean maternal TBG concentration was 1.65 +/- 0.09 mg/100 ml (SEM) and significantly higher (p less than 0.01) than cord blood levels of TBG (1.16 +/- 0.08 mg/100 ml (SEM). Throughout infancy and childhood TBG remained significantly elevated (p less than 0.01) compared to a middle age control group of healthy blood donors. T3, T4 and TSH concentrations behaved postnatally as known from previous studies. The T3 and T4 increase observed immediately after birth was not a secondary phenomenon due to changes in TBG concentration since this globulin did not change significantly during this period.
 ...
PMID:Thyroxine-binding globulin, triiodothyronine, thyroxine and thyrotropin in newborn infants and children. 41 59

A radioimmunoassay for the measurement of l-3,3',5'-triiodothyronine (reverse TO, rT3) has been developed for use with unextracted serum. The highly specific antiserum showed no cross-reactivity with l-3,3'5-triiodothyronine (T3) or tetradiodothyroacetic acid (T4A) and cross-reaction with L-thyroxine (T4) was low enough to be discounted for routine assay purposes. If a normal amount of rT3 was added to serum T4 cross-reactivity decreased considerably. Serial dilutions of hyperthyroid sera gave dose-response curves which were parallel to the rT3 standard curve. Serum concentrations of rT3 (mean+/- SEM) were 0-68 +/- 0-02 nmo1/1 in sixty-seven normal subjects, 0-19 +/- 0-02 nmo1/1 in twelve hypothyroid patients and 1-18 +/- 0-12 nmo1/1 in seventeen hyperthyroid patients. In sixteen patients with TO-toxicosis rTO was 0-42 +/- 0-04 nmo1/1 and eighteen patients with high circulating TBG had a mean rT3 of 0-54 +/- 0-03 nmo1/1.
 ...
PMID:Measurement of serum 3,3',5'-(reverse) T3, with comments on its derivation. 100 77

The effect of recombinant human growth hormone (rhGH) administration on thyroid function was studied in 14 girls with Turner's syndrome for 18 months. All patients were euthyroid and had no documented GH deficiency. Treatment with rhGH, administered as daily subcutaneous injections in a dose of 0.15 IU/kg/day, led to a decrease of serum T4 levels from 124 +/- 4 (mean +/- SEM) to 106 +/- 4 nmol/l (P less than 0.05) after 6 months of therapy. Thereafter serum T4 levels returned progressively to baseline levels. Serum TBG levels increased consistently from 21.9 +/- 0.5 to 24.4 +/- 0.9 mg/l (P less than 0.05) after 3 months. Serum T3 and TSH levels did not change significantly during rhGH administration. The T3/T4 ratio (x 100) increased from 1.9 +/- 0.1 to 2.2 +/- 0.1 (P less than 0.05) after 6 months of treatment and returned thereafter to baseline levels. The observed changes in T3/T4 ratio demonstrated a striking parallelism with the changes in height velocity and plasma IGF-I levels. We conclude that rhGH treatment results in a transient alteration of the thyroid status in girls with Turner's syndrome. The functional importance of this phenomenon, in particular its role in the concomitant growth acceleration, remains to be established.
 ...
PMID:Effect of growth hormone therapy on thyroid status of girls with Turner's syndrome. 203 29

1. We studied a brominated thyroid hormone analogue, SKF L-94901, which has the potential to lower serum cholesterol without adverse cardiovascular effects. This compound is about 50% as active as tri-iodothyronine (T3) in liver nuclear receptor binding in vivo but only 1% as active in vitro and has nearly 200 times more enzyme-inducing activity in liver than in heart. Our aim was to examine the interaction of SKF L-94901 with [125I]T3 binding to the intact nuclei in whole cells, isolated nuclei and nuclear extracts of human HeLa cells and to investigate the binding of this compound to human serum. 2. Relative to thyroxine (T4), the affinity of this compound for T4-binding globulin was 0.0035%, for transthyretin 1.66% and for albumin 1.26%. Low affinity for serum proteins, with a relatively high circulating free fraction, could explain why SKF L-94901 is more potent in vivo than in vitro. 3. Human HeLa cell nuclei, isolated after whole-cell incubations, bound [125I]T3 with high affinity (Kd = 78 +/- 8 pmol/l, mean +/- SEM), which was displaceable by T3 analogues in the order Triac [( 4-(4-hydroxy-3-iodophenoxy)-3,5-di-iodophenyl]acetic acid) greater than T3 greater than T4 much greater than reverse T3. Similar high-affinity (Kd = 58 +/- 6 pmol/l, mean +/- SEM) and identical specificity was observed in high-salt (0.4 mol/l KCl) nuclear extracts. In nuclei of whole cells incubated with [125I]T3 and SKF L-94901, the analogue was 0.8% as potent as T3, whereas in experiments with nuclear extract, the analogue was 7.7% as potent as T3.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:The thyroid hormone analogue SKF L-94901: nuclear occupancy and serum binding studies. 272 Nov 16

The regulatory role of thyroid hormones in the synthesis of milk proteins and functional differentiation of the murine mammary gland has been demonstrated. Further, T4 and T3 and their metabolites are found in both rat and human milk. Since the enhanced metabolic demands of mammo- and lactogenesis may result in increased local hormonal requirements, we examined breast tissue from normal (virgin), pregnant, and lactating female rats, as well as postmenopausal human breast tissue for the presence of a thyroid hormone-binding inhibitor (THBI). This substance, which decreases binding of T4 to serum T4-binding globulin, has been described in rat liver, kidney, muscle, and intestine, and in the circulation of patients with nonthyroidal illnesses. THBI activity in the present study was assessed by equilibrium dialysis in whole tissue homogenates; the ether-soluble fraction was also analyzed for THBI activity by RIA. In a range of 0.8-8.0 mg tissue protein, we found lactating rat breast to contain elevated THBI levels when compared to those found in normal, virgin breast tissue. Half-maximum binding inhibition was achieved at 0.15 mg lactating breast tissue protein, vs. 0.23 mg breast tissue protein and 0.35 mg liver protein in homogenates from normal resting animals. Expressed in tissue milligram equivalents, half-maximum binding inhibition of lactating, 18-day pregnant, and normal rat breast tissue was 0.7, 2.6, and 4.8 mgeq, respectively. Thus, the THBI activity of lactating rat breast tissue was more than 3-fold greater than that of the pregnant rat and 7-fold greater than that found in resting breast tissue. Binding inhibition in postmenopausal human breast tissue was comparable to that of rat breast and liver tissue at low protein concentrations, but the maximum inhibition attainable (205 +/- 6%, n = 3) was significantly lower than that achieved by normal rat breast tissue (338 +/- 6%, n = 6; means +/- SEM). The ether-soluble fraction of breast tissue homogenates was also analyzed employing a THBI-RIA. THBI activity, expressed as percent binding inhibition, was elevated in extracts from lactating rat breast tissue in comparison to tissue from pregnant or normal animals at 6.0, 12.5, and 25 mgeq; the largest differences were observed at 25 mgeq tissue: lactating (57.8 +/- 2.3%) vs. pregnant (46.5 +/- 3.1%, P less than 0.01) vs. normal (41.7 +/- 2.3%, P greater than 0.05); n = 3 in all cases.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:Thyroid hormone-binding inhibitor in normal, pregnant, and lactating rat and postmenopausal human breast tissue. 392 54

To examine the possible effect of progesterone on circulating T4-binding globulin (TBG) in men, RIA measurements of plasma TBG and T4 levels were made before and after weekly administration of 500 mg medroxyprogesterone acetate, im, to men being treated for paraphilia (sexual deviation syndromes). No change in the mean pretreatment plasma TBG concentration was found after 7-29 days [21.5 +/- 1.2 (+/- SEM) to 22.0 +/- 0.9 microgram/ml; n = 14) or 381-415 days (23.0 +/- 2.5 to 23.1 +/- 2.5 micrograms/ml; n = 5) of medroxyprogesterone treatment. Similarly, the mean pretreatment plasma T4 concentration was unaltered by acute (9.7 +/- 0.6 to 9.7 +/- 0.4 microgram/dl; n = 14) or chronic (11.1 +/- 1.2 to 11.4 +/- 1.0 microgram/dl; n = 5) medroxyprogesterone therapy. We conclude that progestational agents alone do not modify circulating TBG or total T4 concentrations in men.
 ...
PMID:Progesterone has no effect on serum thyroxine-binding globulin concentration in men. 393 May 57

Iodized oil (1 ml im) was given to 58 goitrous patients from a mildly iodine-deficient area in Greece. Goiter size, urinary iodine, and serum T4, T3RU, T3, rT3, TSH, thyroxine-binding globulin (TBG), and thyroid autoantibodies were measured before and 1, 3, and 6 months after the injection. Goiter size decreased. Serum T4 remained relatively constant, but TBG decreased and therefore T3RU and FTI increased. Serum T3 and rT3 initially decreased (P less than 0.001) and then increased at the sixth month (P less than 0.001), both showing roughly parallel changes. Serum TSH, initially normal (1.42 +/- 0.11 (SEM) mU/liter), decreased to 0.65 +/- 0.01 and 0.76 +/- 0.05 mU/liter at the third and sixth month (difference from baseline P less than 0.001). Thyroid autoantibodies, both against thyroglobulin and the microsomal antigen, were undetectable before treatment, but became positive in 42.8% of the patients 3 and 6 months later. Three patients developed transient hyperthyroidism. This occurred 3 or 6 months after treatment, and was associated with high titers of thyroid autoantibodies. These results indicate that: 1) transient hyperthyroidism may occur after the administration of iodized oil, possibly because of thyroid tissue necrosis and leakage of hormones, and 2) serum TBG decreases after iodized oil, a finding not previously reported and one whose cause is not known.
 ...
PMID:Thyroid hormone and immunological studies in endemic goiter. 630 89

We have assessed the effect of omeprazole (30 mg daily) on gastric acid secretion as well as on basal hormone levels (fasting gastrin; TSH, T3, T4, TBG; insulin, glucagon, C-peptide; prolactin, testosterone, 17-beta-oestradiol, dihydroepiandrosterone, cortisol and PTH) in 8 healthy volunteers before and after a 28 day treatment. On day 29, i. e. one day after the last omeprazole dose, mean stimulated acid output was still reduced from 27.4 +/- 3.5 mmol H+/h (+/- SEM) to 7.8 +/- 1.4 mmol H+/h (72% inhibition). Fasting gastrin levels were raised from 55.5 +/- 6.8 pg/ml to 80.9 +/- 6.7 pg/ml (33% increase). On day 39, stimulated gastric acid secretion and fasting gastrin levels have been returned to pretreatment values. Basal levels of prolactin, testosterone, TSH, T3, T4, TBG, cortisol, PTH, 17-beta-oestradiol, insulin, glucagon, c-peptide, dihydroepiandrosterone remained unchanged by a 28-day omeprazole treatment. Omeprazole is a highly effective antisecretory compound without any effect on the basal hormone levels tested. Even after 28 days its effect on acid secretion and fasting gastrin levels was fully reversible.
 ...
PMID:[4 weeks' administration of omeprazole: effect on acid behavior and basal hormone levels]. 674 Dec

The non-steroidal anti-inflammatory agent fenclofenac competitively inhibits the binding of thyroxine(T4) and triiodothyronine (T3) by thyroxine-binding globulin(TBG). Eight male volunteers completed a 4-week study during which they took fenclofenac 600 mg twice daily. The concentration of fenclofenac in serum reached a plateau after 1 week of therapy after which the mean concentration(+/SEM) of the drug in serum was 78.6 o.2 mg/1. During the steady state period on treatment there were reductions of the mean serum concentrations of total T4 to 35% (P less than 0.001), total T3 to 55% (P less than 0.001), free T4 to 69% (P less than 0.001) and free T3 to 90% (NS) of the respective pretreatment values. There were also significant changes in the concentrations of thyrotropin and reverse T3 in serum. After starting treatment with fenclofenac serum concentrations of thyrotrophin fell to a nadir after 2-4 days at which time the mean concentration was 34% (P less than 0.01) of the pretreatment value, whilst reverse T3 values increased to a maximum of 136% (P less than 0.001) of the pretreatment values over 1-2 days. There was subsequently an increase of the thyrotrophin and a reduction in reverse T3 concentrations to normal by 2 weeks of pretreatment. Transient pituitary suppression was also suggested by the response to to thryotrophin-releasing hormone (TRH): 7 days after starting fenclofenac the mean thyrotrophin response was 62% (P less than 9.001) of the pretreatment value. After 4 weeks of fenclofenac the response of TRH had returned to normal. After discontinuing fenclofenac there was a transient increase in the mean concentration of thyrotrophin in serum, to 129% of the pretreatment value (P less than 0.001), with a subsequent return to normal. Four weeks after discontinuing fenclofenac the serum concentrations of thyroid hormones and thyrotrophin were normal.
 ...
PMID:The effect of fenclofenac on thyroid function. 679 98